期刊
FRONTIERS IN PHARMACOLOGY
卷 4, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2013.00018
关键词
poly(ADP-ribose) polymerase; PARP-inhibitors; synthetic lethality; potentiation of anti-cancer therapy; resistance to PARP-inhibitors; DNA damage; DNA repair
资金
- NSERC
- Laval University
- CIHR [89964]
The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARR) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers. Thus, usage of PARP-inhibitors (PARPi) in cancer therapy is bound to increase with time, but resistance of cancer cells to PARPi is also beginning to be observed. Here we review different known and potential mechanisms by which: (i) PARPi kill cancer cells; and (ii) cancer cells develop resistance to PARPi. Understanding the lethality caused by PARPi and the countermeasures deployed by cancers cells to survive PARPi will help us rationalize the use of this new class of drugs in cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据